Pfizer Just Locked Next Growth Path: What Investors Should Know
Pfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
Recognize warning signs your budget is bad and learn practical tweaks to restore balance and reliability.
19,039 articlesPfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
A practical, investor-friendly look at Gambling.com Group's Q1 2026 earnings. This deep dive breaks down revenue driv...
The kiplinger letter spots trap emerges as a focal point in retirement planning as 401(K) plans weigh adding private ...
Late Saturday, gunfire near the White House prompted a rapid security response. Authorities reported no injuries, whi...
A 67-year-old with $620,000 inherited 401(k) balance faces a looming $80,000 federal tax hit under the SECURE Act’s 1...
CubeSmart sits in a crowded self-storage field. This guide breaks down the key indicators I watch to assess whether C...
Eagle Point Credit Company touts an 18% yield, yet its portfolio centers on CLO equity tranches—the most volatile seg...
Pediatrix Medical Group stock tumbled on Thursday after earnings highlighted modest revenue pressures and GAAP vs non...
SpaceX's potential IPO has investors weighing a massive valuation against current profitability. This article breaks ...
Chemours faces a year of nuanced cycles in pigments and fluorochemicals. This guide breaks down what to watch in chem...
The AI IPO race is accelerating as OpenAI joins the fray after Anthropic. This article breaks down what the filing me...
A Life360 board director recently sold several thousand shares after exercising options, timing that coincides with a...